Sung Ji Nam
Stock Analyst at Scotiabank
(2.11)
# 2,823
Out of 4,862 analysts
78
Total ratings
41.54%
Success rate
-6.43%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $18.91 | +111.53% | 6 | May 21, 2025 | |
BDSX Biodesix | Maintains: Sector Outperform | $3 → $2 | $0.29 | +587.52% | 2 | May 21, 2025 | |
MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $5.08 | +18.11% | 4 | May 21, 2025 | |
GH Guardant Health | Maintains: Sector Outperform | $52 → $57 | $49.23 | +15.78% | 5 | May 5, 2025 | |
TMO Thermo Fisher Scientific | Maintains: Sector Perform | $650 → $605 | $403.00 | +50.12% | 14 | Apr 25, 2025 | |
BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $3.60 | +11.14% | 6 | Apr 2, 2025 | |
PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $1.19 | +68.78% | 5 | Mar 25, 2025 | |
EXAS Exact Sciences | Maintains: Sector Outperform | $70 → $73 | $53.65 | +36.07% | 2 | Feb 24, 2025 | |
ADPT Adaptive Biotechnologies | Maintains: Sector Outperform | $10 → $12 | $10.27 | +16.85% | 2 | Feb 13, 2025 | |
WAT Waters | Upgrades: Sector Outperform | $430 → $450 | $342.56 | +31.36% | 2 | Feb 13, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $88 → $90 | $50.57 | +77.97% | 2 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $33.52 | +84.96% | 5 | Feb 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Perform | $265 | $200.87 | +31.93% | 1 | Dec 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $26.58 | +65.54% | 4 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $18.74 | +86.77% | 4 | Nov 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $176 → $164 | $87.07 | +88.35% | 9 | Aug 15, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $5.57 | +7.72% | 2 | Jun 29, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $20.67 | - | 3 | Nov 24, 2020 |
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $18.91
Upside: +111.53%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $3 → $2
Current: $0.29
Upside: +587.52%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $5.08
Upside: +18.11%
Guardant Health
May 5, 2025
Maintains: Sector Outperform
Price Target: $52 → $57
Current: $49.23
Upside: +15.78%
Thermo Fisher Scientific
Apr 25, 2025
Maintains: Sector Perform
Price Target: $650 → $605
Current: $403.00
Upside: +50.12%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $3.60
Upside: +11.14%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $1.19
Upside: +68.78%
Exact Sciences
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $53.65
Upside: +36.07%
Adaptive Biotechnologies
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $10.27
Upside: +16.85%
Waters
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $342.56
Upside: +31.36%
Feb 6, 2025
Maintains: Sector Outperform
Price Target: $88 → $90
Current: $50.57
Upside: +77.97%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $33.52
Upside: +84.96%
Dec 23, 2024
Initiates: Sector Perform
Price Target: $265
Current: $200.87
Upside: +31.93%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $26.58
Upside: +65.54%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $18.74
Upside: +86.77%
Aug 15, 2024
Maintains: Sector Outperform
Price Target: $176 → $164
Current: $87.07
Upside: +88.35%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $5.57
Upside: +7.72%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $20.67
Upside: -